Norfolk Southern Corporation vs TransMedics Group Inc — how do they compare? Norfolk Southern Corporation trades at $335.84 (market cap $75.15B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Norfolk Southern Corporation is far larger — about 24.2× TransMedics Group Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| NSC | TMDX | |
|---|---|---|
Market Cap | $75.15B | $3.10B |
Sector | Technology | Technology |
52-Week High | $350.66 | $150.42 |
52-Week Low | $272.35 | $61.99 |
Enterprise Value | $90.70B | $3.49B |
Dividend Yield | 1.61% | — |
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $335.41, up 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $369.67. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $3.52 exceeding expectations, driven by record revenue and volume growth. A pending merger with Union Pacific and a recent dividend declaration highlight ongoing corporate activity.
The outlook is positive, supported by strong operational performance and favorable industry trends, though risks include integration challenges from the merger, premium valuation metrics, and potential economic headwinds affecting freight demand. Investor sentiment is mixed, with analysts predominantly holding a neutral to bullish stance.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Trailing returns across standard periods
Latest headlines on both assets
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →